Last reviewed · How we verify

NCT07117071

Prevalence of Fuchs Endothelial Corneal Dystrophy in a Population of Dermatology Patients.

Completed Last updated 12 August 2025
What this trial tests

trial testing collection of medical data in Fuchs Endothelial Corneal Dystrophy in 1,200 participants. Completed in 31 December 2024.

Timeline
2 January 2024
Primary endpoint
31 December 2024
31 December 2024

Quick facts

Lead sponsorCentre Hospitalier Universitaire de Saint Etienne
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,200
Start date2 January 2024
Primary completion31 December 2024
Estimated completion31 December 2024
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Who can join

18 and older, any sex, with Fuchs Endothelial Corneal Dystrophy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The prevalence of Fuchs Endothelial Corneal Dystrophy (FECD) varies from 3.7 to 21.6% of adults depending on the population studied (country and age class), the method of diagnosis and the definition adopted. In the absence of available data for France, we analyzed the prevalence of Fuchs Endothelial Corneal Dystrophy (FECD) in a specific sub-population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of collection of medical data

Trials testing the same drug.

Other recruiting trials for Fuchs Endothelial Corneal Dystrophy

Currently open trials in the same condition.

Other Centre Hospitalier Universitaire de Saint Etienne trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07117071.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing